Abstract: According to the present invention, a protein having peptide-synthesizing activity, a DNA encoding the protein, a recombinant DNA containing the DNA, a transformant obtained via transformation with the recombinant DNA, a process for producing a protein having peptide-synthesizing activity using the transformant and the like, a process for producing a peptide using a protein having peptide-synthesizing activity, and a process for producing a peptide using as an enzyme source a culture or the like of a transformant or a microorganism producing a protein having peptide-synthesizing activity are provided.

Abstract: It is disclosed herein that isolated lymphocytes, such as human B-cells and CD4+ T-cell can be used to determine an amount of lymphocyte-associated anthrax lethal toxin activity present. Methods of using isolated lymphocytes to identify anthrax therapeutic agents and to determine the efficacy of a potential anthrax therapeutic are disclosed. Methods are also provided for diagnosing and treating anthrax infections.

Abstract: Apparatus suitable for use in the prevention and treatment of burn induced compartment syndrome facilitates the rapid and efficient deployment of enzymatic compositions to the affected limb or limbs of a burn victim suffering from a circumferential burn. The apparatus includes a flexible, water-impermeable generally cylindrical covering layer. The covering layer has an inner surface facing the limb and an outer surface. The covering layer has a proximal sealable open end through which the burned limb is inserted and a distal closed end. An enzymatic escharotomy agent is contained within the covering layer. The covering layer retains the enzymatic escharotomy agent in close proximity to the burned limb, and the apparatus is enclosed within a sterile sealed package evacuated from moisture.

Abstract: The invention relates to the use of a Factor VIIa for the manufacture of a medicament for treatment of a condition affectable by Factor VIIa, said medicament being for subcutaneous, intramuscular or intradermal administration, and to the use of a Factor VIIa for the manufacture of a medicament for treatment of a condition affectable by Factor VIIa, wherein said medicament, when administered subcutaneously, intradermally or intramuscularly, shows a prolonged biological half-life.

Abstract: Disclosed herein is a pharmacophore model for inhibiting anthrax lethal factor protease activity which comprises a first aromatic center A, a second aromatic center B, a first polar center C, a second polar center D, a third polar center E, and a neutral linker F. Also disclosed are small molecules fitting the pharmacophore model and compositions and methods of using thereof.

Abstract: Provided in the present invention is an alkaline protease wherein an amino acid residue at (a) position 65, (b) position 101, (c) position 163, (d) position 170, (e) position 171, (f) position 273, (g) position 320, (h) position 359 or (i) position 387 of SEQ. ID NO:1 or at a position corresponding thereto has been selected from the following amino acid residues: position (a): proline, position (b): asparagine, position (c): histidine, aspartic acid, phenylalanine, lysine, asparagine, serine, isoleucine, leucine, glutamine, threonine and valine, position (d): valine and leucine, position (e): alanine, glutamic acid, glycine and threonine, position (f): isoleucine, glycine and threonine, position (g): phenylalanine, valine, threonine, leucine, isoleucine and glycine, position (h): serine, leucine, valine, isoleucine and glutamine, position (i): alanine, lysine, glutamine, glutamic acid, arginine and histidine.

Abstract: The present application relates to methods for growing crystals of both the uncomplexed and complexed forms of ?-secretase (BACE) polypeptide. The present application also relates to crystalline forms of uncomplexed BACE and the three-dimensional structure of BACE, as determined from the crystals. In addition, the present application relates to the use of crystalline forms of BACE to identify ligands, preferably inhibitors (antagonists), which bind to, and preferably inhibit the enzymatic activity of, BACE. Furthermore, the present application relates to nucleic acid sequences encoding BACE polypeptide, and methods for making BACE in greater quantity than prior methods, resulting in more effective crystallization.

Abstract: The present invention is directed to novel acid proteases and more specifically to NSP24 family proteases and NSP25 family proteases including biologically active fragments thereof and to nucleic acid molecules encoding said proteases. Also provided are vectors and host cells including nucleic acid sequences coding for the proteases, methods for producing the proteases, enzyme compositions and methods employing said proteases.

Abstract: The present invention provides stable compositions comprising a perhydrolase enzyme, a hydrogen peroxide source, and an ester substrate that efficiently generate aqueous peracid solutions. The generated peracid solutions are suitable for decontaminating and/or sanitizing a wide range of materials and equipment contaminated with pathogens or toxic chemicals. In one preferred embodiment, the stable composition comprises an acyl transferase enzyme, sodium percarbonate, and propylene glycol diacetate, and is stable for 30 days or longer. Upon addition to water, the composition is activated and generates an aqueous solution with a high ratio of peracetic acid to acetic acid.

Abstract: Many suppliers claimed their products have been Tachyonized™ since the discovery and commercialization of Tachyonized™ products by Advanced Tachyon Technologies International. Genuine materials that have been Tachyonized have demonstrated a range of beneficial properties to biological organisms and processes. However, the market has been saturated with competitors making such claims without any foundation. Accordingly, the inventive process provides a simple and rapid test method to confirm the authenticity of Tachyonized materials.

Abstract: Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.

Abstract: The synthesis, biological evaluation, and molecular modeling of alkoxysuccinyl-peptidyl-haloalkyl ketones for use as proteinase K inhibitors are described. Sample preparation processes for in situ RNA or DNA analysis using such inhibitors, methods and compositions therefor are provided.

Abstract: The present disclosure provides crystals of and structural coordinates of Hepatocyte growth factor activator with and without bound pseudo-substrate or inhibitor. In a specific embodiment, a crystal structure of activated HGFA complexed with a Kunitz domain inhibitor is provided. The crystals and crystal structures are useful, for example, in the design and synthesis of inhibitors of HGFA.

Abstract: A new strain Bacillus sp. P203 (Bacillus plakortiensis) is disclosed. Isolated mature functional polypeptide which is obtainable from the bacterium strain Bacillus sp. P203 deposited under accession number DSM 17419 are disclosed.

Abstract: The present invention relates to anti-angiogenic polypeptides derived from the non catalytic C-terminal hemopexin-like domain of the metalloproteinase MMP-2. The invention also provides pharmaceutical compositions comprising said anti-angiogenic polypeptides and methods for using said polypeptide for treating angiogenic diseases, and in particular for treating cancer.

Abstract: Stable compositions comprising a nucleic acid binding support material comprising a substrate with functional groups attached to the substrate; a lysing enzyme; a water dispersible matrix material; and a saccharide, methods of using the compositions, and products and devices which include the compositions are disclosed.

Abstract: The present invention relates to novel JP170 like subtilases from wild-type bacteria, hybrids thereof and to methods of construction and production of these proteases. Further, the present invention relates to use of the claimed subtilases in detergents, such as a laundry or an automatic dishwashing detergent.

Abstract: The present invention relates to structural studies of dipeptidyl peptidase I (DPPI) proteins, modified dipeptidyl peptidase I (DPPI) proteins and DPPI co-complexes. Included in the present invention is a crystal of a dipeptidyl peptidase I (DPPI) and corresponding structural information obtained by X-ray crystallography from rat and human DPPI. In addition, this invention relates to methods for using structure co-ordinates of DDPI, mutants hereof and co-complexes, to design compounds that bind to the active site or accessory binding sites of DPPI and to design improved inhibitors of DPPI or homologues of the enzyme.

Abstract: Isolated anti-cancer peptides are disclosed which are characterized by the amino acid sequences TLTSGGGAIALPPSMAAPPLGPVAPLTGAIHAPTXG; TLSTATGGAIPPVAAMPPGLVAPTHGPAIHP; CCATSGPCGAVMILTPHLTA; MTLTTGSGAIAPAMPPGLPPHTGAIHAPM; and NXVPVSVEGYXQITLDSITX and a significant in vitro binding affinity for gp96. The peptides exhibit anti-tumor, anti-cancer activity in vivo. Also disclosed is an isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.

Abstract: The invention provides methods for efficient recombinant expression, refolding, and purification of Beta-site APP cleaving enzyme (BACE) polypeptides. In various aspects, the method includes the steps of expressing a recombinant construct in bacteria, dissolving inclusion bodies with a denaturant at high pH in the presence of a reducing agent, diluting the solubilized BACE polypeptide in an aqueous solution at a temperature of about 1° C. to 15° C., and incubating the diluted sample at a temperature of about 4° C. to 15° C. until the recombinant BACE polypeptide folds into an active enzyme.

Abstract: The present invention relates to methods for producing variants of a parent JP170 subtilase and of a parent BPN? subtilase and to JP170 and BPN? variants having altered properties as compared to the parent JP170/BPN? subtilase.

Abstract: The present invention relates to biocatalytic asymmetric reduction for the preparation of 2-amino-[5-(1-hydroxy-2-hydroxy or halogen-ethyl)]-pyrazine derivatives of the formula wherein R is lower alkylcarbonyl or an amino protecting group and R1 is hydroxy or halogen. The compounds are key intermediates in the manufacture of a glucokinase activator.

Abstract: Human BACE polypeptides having modifications to the N-linked glycosylation sites including one or more of the following amino acid substitutions: S174I, N223A, N153Q and N354S. DNA sequences, vectors, and host cells for producing the polypeptides. Crystalline protein compositions formed from the purified polypeptides. Methods of screening for compounds that inhibit A? using the polypeptides.

Abstract: There is presently provided a complex of a micelle formed from a cationic polymer and a protein, and a method using the complex to deliver the protein into a cell.

Abstract: The present invention relates to novel subtilase variants exhibiting improvements relative to the parent subtilase in one or more properties including: wash performance, thermal stability, storage stability or catalytic activity. The variants of the invention are suitable for use in e.g., cleaning or detergent compositions, such as laundry detergent compositions and dish wash compositions, including automatic dish wash compositions.

Abstract: The present invention provides a venene haemocoagulase gene and its expression for the functional protein. The haemocoagulase gene of the present invention has a nucleotide sequence shown by the sequence list SEQ ID NO: 1 or the mutated nucleotide sequence formed by replacement, depletion, or addition of one or more nucleotide based on the said nucleotide sequence with an equivalent function. The said haemocoagulase has amino acid sequence shown by SEQ ID NO: 2. Haemocoagulase of the present invention has an obvious hemostatic effect, a broad effective dose range, safe and reliable application, which creates good conditions for the development of genetic engineering products of recombinant haemocoagulase in the future.

Abstract: An inhibitor bound form of human beta secretase, also known as memapsin 2 and BACE, particularly in a glycosylated form as expressed in Chinese hamster ovary (CHO), HEK293 cells, or in insect cells as part of a Baculovirus expression system has been crystallized, and the three dimensional x-ray crystal structure has been solved to 3.2 ? resolution. The x-ray crystal structure is useful for solving the structure of other molecules or molecular complexes, and designing inhibitors of human beta secretase activity.

Abstract: A method of enzymatically producing a protein hydrolysate from a protein substrate is described, wherein a proline-specific endoprotease or a composition containing a proline-specific endoprotease and optionally a subtilisin or a metallo endoprotease, and other enzymes such as carboxypeptidases, is used to produce a protein hydrolysate enriched in peptide fragments having a carboxy-terminal proline residue. Such protein hydrolysates may be used as such or to reduce bitterness in foods nutritionally supplemented by protein hydrolysates, as well as to produce hydrolysate-containing foodstuffs having low antigenicity.

Abstract: A method of removing an enzyme from a liquid enzyme reaction mixture used in a hydrolysis reaction or a base exchange reaction of a phospholipid is provided. The method includes the step of treating the liquid enzyme reaction mixture with a solvent mixture of water and an organic solvent, wherein the solvent mixture includes an inorganic metal salt, to remove the enzyme. Enzymes included in the reaction product can be easily removed without a treatment such as heating, and thus it becomes possible to easily produce various phospholipids that have a reduced risk of inducing an allergy, that retain a high quality and that have excellent storage stability.

Abstract: Provided herein is are polypeptides that include the protease domain of a type II transmembrane serine protease (MTSP) as a single chain. Methods using the polypeptides to identify compounds that modulate the protease activity of an MTSP are provided. Also provided are MTSPs designated MTSP3 and MTSP4 and a form of an MTSP designated MTSP6.

Abstract: The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.

Abstract: A combination enzyme product consisting of a glutamine specific endoprotease and a prolyl endopeptidase is provided. Both enzymes are active and stable in the stomach and can therefore be administered as lyophilized powders or simple capsules/tablets. A ratio of the two enzymes is used to maximize their synergy.

Abstract: The present invention relates to a suspension culture process for producing an enzyme, comprising the steps of providing a minimal medium, which contains deionised water, mineral salts and an organic carbon source, in a vessel; inoculating the minimal medium with a fungus; incubating the minimal medium at a pH value of 1-4 for a period of time which is sufficient for the fungus to be optically visible in the minimal medium, and obtaining the enzyme, wherein the minimal medium and the vessel are not sterilised. In addition, the invention relates to an enzyme obtainable by the process according to the invention.

Abstract: The invention provides methods for purifying blood coagulation Factor XI from biological fluids, the methods comprising a step of hydrophobic charge induction chromatography (HCIC).

Abstract: The use of the single nucleotide polymorphism (SNP) of the ADAMTS4 gene for the identification of cardiovascular and peripheral vascular disorders or of an increased risk for developing cardiovascular and peripheral vascular disorders in a biological sample taken from an individual to be examined; the use of ADAMTS4 for identifying substances active in preventing and/or treating cardiovascular and peripheral vascular disorders and methods for doing so.

Abstract: The invention relates to a process for the recombinant production of a heterologous polypeptide of interest, comprising, (i) cultivation of a bacterial host cell which is transformed with an expression vector which comprises a nucleic acid molecule which codes for a fusion polypeptide, the fusion polypeptide comprising a derivative of an autoprotease Npro of Pestivirus, wherein at least one cysteine residue of the naturally occuring autoprotease Npro of Pestivirus is replaced by another amino acid residue, and a second polypeptide which is connected to the first polypeptide at the C-terminus of the first polypeptide in a manner such, that the second polypeptide is capable of being cleaved from the fusion polypeptide by the autoproteolytic activity of the first polypeptide, said second polypeptide being a heterologous polypeptide, wherein cultivation occurs under conditions which cause expression of the fusion polypeptide and formation of corresponding cytoplasmic inclusion bodies, (ii) isolation of the inclus

Abstract: The invention disclose a method for purifying microbial protease, comprising:(i) providing an aqueous liquid sample containing a microbial protease, and a separation medium comprising a base matrix and a plurality of attached ligands that are capable of binding to microbial protease;(ii) contacting separation medium with the sample under conditions permitting binding of microbial protease to the separation medium; and (iii) desorbing microbial protease from the separation medium, wherein the base matrix is hydrophilic and the plurality of ligands are hydrocarbon groups in which all carbon atoms are sp3-hybridised.

Abstract: The use of matrix metalloproteinases, mutated and not mutated, for the preparation of pharmaceutical compositions useful in the treatment of pathologies associated with an accumulation of matrix bio-polymers and/or an excess of TIMPs (Tissue Inhihitors MetalloProteinases) is described; mutated matrix metalloproteinases, in which at least an aminoacid residue in a definite position in the protein, has been mutated into a hydrophilic and/or charged aminoacidic residue, obtaining an increased stability toward autoproteolysis are also described.

Abstract: A purified recombinant batroxobin with high specific activity, which has the following properties: (a) the batroxobin has a molecular weight of 29-32 kDa; (b) at least 90% of the batroxobin have 6 pairs of disulfide bonds which correctly match at Cys7-Cys139, Cys26-Cys42, Cys74-Cys230, Cys118-Cys184, Cys150-Cys163 and Cysl174-Cys199; (c) positions 146 and 225 in SEQ ID NO:1 are modified as N-glycosylation; and (d) the specific activity of the batroxobin is equal to or greater than 1500 KU/mg protein.

Abstract: A fragmenting reaction of peptide is achieved while maintaining the isolated state of peptide. Isolated peptide fractions isolated by electrophoresis are prepared in flow paths. Subsequently, prepared peptide fractions are dried by each of the flow paths. Then, dried peptide fractions are in contact with protease. Then, independent liquid membranes of a solvent are formed over the surfaces of peptide fractions, which have been in contact with protease, disposed on the flow paths, respectively.

Abstract: The invention concerns a nucleic acid encoding a recombinant bifunctional fusion peptidoglycan hydrolase protein formed from a nucleic acid encoding a peptidoglycan hydrolase module and a nucleic acid encoding a second peptidoglycan hydrolase module. The fusion, dual (or multiples thereof) peptidoglycan hydrolase modules can be used to treat disease caused by the bacteria for which the individual modules of the fusion protein are specific.

Abstract: Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that retain normal levels of anti-apoptotic activity are provided. Two examples of such recombinant APC mutants are KKK191-193AAA-APC and RR229/230AA-APC. APC variants and prodrugs of the invention have the desirable property of being cytoprotective (anti-apoptotic effects), while having significantly reduced risk of bleeding. The invention also provides a method of using the APC variants or prodrugs of the invention to treat subjects who will benefit from APC's cytoprotective activities that are independent of APC's anticoagulant activity. These subjects include patients at risk of damage to blood vessels or tissue in various organs caused, at least in part, by apopotosis.

Abstract: The present invention relates to regulatory cells, which are capable of restoring, maintaining or improving the stable cartilage phenotype of expanded and passaged chondrocytes. These regulatory cells are also capable of directing precursor and stem cells into the chondrogenic lineage. An enriched population of regulatory cells can be obtained by harvesting the non-adherent cells in the culture medium of a monolayer culture of PO chondrocytes.

Abstract: A method for the detection in a body fluid of perlecan polypeptide fragments that are biomarkers of tumor metastasis, and antibodies for detecting these fragments are described. An immunoassay kit for detecting the presence of these biomarkers in a body fluid, such as serum or urine, is also described.

Abstract: The present invention relates to the use of a proline-specific protease for accelerating the beer brewing process. In particular, it relates to the use of a proline-specific protease for accelerating the beer brewing process by shortening and simplifying the stabilisation phase of beer production. The stabilisation period as such can be omitted from the beer making process hereby saving significant costs and adding to the flexibility of beer producing plants.

Abstract: The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel PCSK9b and PCSK9c polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: The present invention provides methods and compositions to reduce growth of microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions.

Abstract: The present invention relates to a novel protease, a polynucleotide encoding the protease, and a fibrinolytic agent comprising the same. The protease is obtained from a new gene source by using metagenomic library technology, and can replace the conventional fibrinolytic agent.

Abstract: The present invention relates to chimeric proteins with cell-targeting specificity and apoptosis-inducing activities. In particular, the invention is illustrated by a recombinant chimeric protein between human interleukin-2 (IL2) and Bax. The chimeric protein specifically targets IL2 receptor (IL2R)-expressing cells and induces cell-specific apoptosis.

Abstract: The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the rate of Gal?1,3Gal glycan moieties is comprised between 0 and 4%.